Genotoxicity Testing of Single-Use Consumables: Standards, Methods, and Regulatory Compliance

Genotoxicity testing of single-use consumables evaluates whether extractable and leachable substances released from disposable medical, bioprocessing, and laboratory products can damage DNA, genes, or chromosomes. Conducted in accordance with ISO 10993-3, ISO 10993-12, and OECD test guidelines, these assays form a mandatory part of risk-based biological evaluation and regulatory submissions for single-use systems worldwide. This article explains the technical rationale, sample scope, testing items, methodologies, and practical applications of genotoxicity assessment for single-use consumables.

Technical Overview

Genotoxicity refers to the ability of a chemical substance to damage genetic material, producing DNA strand breaks, gene mutations, base-pair substitutions, frameshift mutations, or structural and numerical chromosomal aberrations. Single-use consumables, including polymer-based bioprocess bags, tubing, filters, syringes, infusion sets, and laboratory plasticware, are manufactured from materials that may contain residual monomers, oligomers, plasticizers, antioxidants, slip agents, colorants, adhesives, and sterilization residues such as ethylene oxide or radiolysis products. When these components contact patients, pharmaceutical formulations, or cell culture systems, extractable and leachable chemicals can migrate into the contacted medium and present a potential genotoxic hazard.

Genotoxicity evaluation of single-use consumables is governed by a risk-based framework defined in ISO 10993-1 (Biological evaluation of medical devices) and ISO 10993-3 (Tests for genotoxicity, carcinogenicity and reproductive toxicity). ISO 10993-12 specifies sample preparation and reference materials, while ISO 10993-18 (chemical characterization) and ISO 10993-17 (toxicological risk assessment) support the interpretation of biological results through analytical identification and safety margin calculation. Because no single assay can detect all genotoxic mechanisms, testing is performed as a battery that combines bacterial reverse mutation assays with mammalian cell cytogenetic tests, supplemented by in vivo testing when in vitro results are positive or when the risk assessment requires additional evidence.

For bioprocess single-use systems used in biopharmaceutical manufacturing, genotoxicity assessment is further integrated with extractables and leachables studies following industry protocols such as the BioPhorum extractables protocol, USP general chapters, and ICH M7-style assessment of mutagenic impurities, ensuring that patient exposure to leached substances remains below thresholds of toxicological concern.

Testing Samples

Single-Use Bioprocess Components

Flexible films, mixing bags, storage bags, sterilizing-grade and depth filters, tubing, connectors, sterile welds and seals, sensors, and sampling systems used in upstream and downstream biopharmaceutical production. Test articles are typically extracted at exaggerated surface-area-to-volume ratios to simulate worst-case leachables profiles.

Medical Device Consumables

Hypodermic syringes, needles, IV infusion sets, blood collection and transfusion bags, catheters, drainage sets, dialysis consumables, wound dressings, anesthesia circuits, and sterilization packaging that contact tissue, blood, or body fluids for limited, prolonged, or permanent durations.

Laboratory Consumables and Plasticware

Pipette tips, centrifuge tubes, culture flasks, multiwell microplates, cell strainers, cryovials, petri dishes, and PCR consumables manufactured from polypropylene, polystyrene, polyethylene, cyclic olefin copolymers, or fluoropolymers, where leached substances may affect assay reliability or cell-based research outcomes.

Pharmaceutical Packaging and Drug Delivery Components

Primary packaging such as vials, elastomeric stoppers, prefilled syringe barrels and plungers, cartridges, and blister foils, as well as combination product delivery components, evaluated as part of container closure and drug-device compatibility programs.

Testing Items

A genotoxicity testing program for single-use consumables typically includes the following items, selected according to the nature of body or product contact and the applicable regulatory pathway:

• Bacterial reverse mutation test (Ames test) according to OECD Test Guideline 471, detecting frame-shift and base-pair substitution mutagens in Salmonella typhimurium and Escherichia coli strains.
• In vitro mammalian chromosomal aberration test according to OECD Test Guideline 473, detecting structural chromosome damage in Chinese hamster cells or human lymphocytes.
• In vitro mammalian cell micronucleus test according to OECD Test Guideline 487, detecting chromosome breakage and whole-chromosome loss using cytokinesis-block methodology.
• Mouse lymphoma assay (TK mutation assay) according to OECD Test Guideline 490, detecting both gene mutations and chromosomal events at the thymidine kinase locus.
• In vivo mammalian erythrocyte micronucleus test according to OECD Test Guideline 474, evaluating chromosomal damage in rodent bone marrow when in vitro results are positive or when regulatory reviewers require in vivo confirmation.
• Mammalian alkaline comet assay according to OECD Test Guideline 489, identifying DNA strand breaks in target tissues, frequently combined with the micronucleus test in integrated study designs.
• Extractables and leachables profiling by GC-MS, LC-MS/MS, and ICP-MS, with toxicological assessment of identified compounds against ISO 10993-17 safety margins and mutagenic thresholds of toxicological concern.

Testing Methods

Sample Preparation and Extraction

Test articles are extracted following ISO 10993-12 using standardized ratios, commonly 3 cm² per mL for surfaces or 0.2 g per mL for irregular solids, in both polar media (physiological saline, water, or culture medium) and non-polar or mixed solvents (for example, ethanol/water mixtures or n-hexane for exhaustive screening). Extraction conditions include 37°C for 72 hours to simulate clinical use, and accelerated conditions such as 50°C for 72 hours, 70°C for 24 hours, or 121°C for 1 hour to generate exaggerated challenge extracts. Extraction vehicles are selected to be compatible with the biological test systems and to avoid solvent-mediated cytotoxicity or osmotic interference.

Bacterial Reverse Mutation Test

The Ames test is performed with a panel of five strains, typically S. typhimurium TA98, TA100, TA1535, TA1537 (or TA97a), and TA102 (or E. coli WP2 uvrA), both with and without an exogenous metabolic activation system, usually rat liver S9 fraction at 10 percent. Plate incorporation and pre-incubation procedures are both accepted, with multiple dose levels established below the inhibition concentration, concurrent negative and positive controls, and triplicate plating. A test article is considered mutagenic when a dose-related increase in revertant counts reaches at least twice the vehicle control value for most strains, or three times for TA102, with biological relevance confirmed by replicate experiments.

In Vitro Chromosomal Aberration and Micronucleus Tests

Mammalian cell assays employ CHO, CHL, V79, or human lymphocyte cultures with short-term exposure, for example 3 and 6 hours, in the presence and absence of S9, and continuous exposure for approximately 1.5 cell cycles without S9. Dose levels are set using cytotoxicity benchmarks such as approximately 55 percent reduction in relative population doubling or mitotic index, and concentrations causing excessive cytotoxicity or precipitation are excluded from scoring. Metaphase analysis of 100 to 200 cells per concentration records gaps, breaks, exchanges, rings, dicentrics, and complex rearrangements, while the in vitro micronucleus test scores at least 2,000 binucleated cells per concentration, supported by cytostasis indices and, where appropriate, kinetochore or centromere staining to distinguish clastogenic from aneugenic modes of action.

In Vivo Genotoxicity Testing

When in vitro results are positive or the risk assessment requires animal data, the in vivo micronucleus test is conducted in rodents, usually mice or rats, with extract administration at maximum tolerated or maximum feasible doses, and bone marrow sampling at 24 and 48 hours. At least 2,000 polychromatic erythrocytes per animal are scored for micronuclei, with normochromatic erythrocyte ratios confirming bone marrow exposure. Follow-up or integrated comet assays in liver or blood cells provide additional evidence on primary DNA damage at the site of contact or systemically.

Data Evaluation and Reporting

Studies are validated against acceptance criteria for vehicle and positive controls, concurrent cytotoxicity, and assay sensitivity. Results are interpreted using biological relevance criteria, dose-response statistics, and replication, and are reported with full raw data, GLP or study quality statements, and conclusions that feed into the overall biological evaluation plan. Positive findings trigger options including chemical identification of the responsible leachable, toxicological risk assessment against permissible exposure limits, material reformulation, or additional in vivo follow-up testing.

Applications

Genotoxicity testing of single-use consumables supports product development, quality assurance, and market access across the medical device, biopharmaceutical, and laboratory products industries. Typical application scenarios include:

• Regulatory submissions to authorities such as the NMPA, FDA under 510(k) or PMA pathways, EU MDR notified body review, and other regional registrations requiring ISO 10993 biological evaluation documentation.
• Qualification of single-use systems in biopharmaceutical manufacturing, demonstrating that process-contact materials do not introduce mutagenic leachables into drug substance or drug product.
• Container closure and combination product compatibility studies for prefilled syringes, vials, and elastomeric closures in coordination with drug stability programs.
• Material selection and design change control, including supplier qualification, resin or film changes, alternative sterilization methods, and equivalency assessments for product transfers.
• Investigative studies following positive screening results, failed cell culture performance, or field complaints potentially linked to leachable-mediated DNA damage.

FAQ

Question: What is the standard genotoxicity battery for single-use consumables?

Answer: The most common battery combines the Ames test with either the in vitro chromosomal aberration test or the in vitro micronucleus test, covering gene mutations and chromosomal damage. An in vivo micronucleus test is added when in vitro results are equivocal or positive, or when the contact duration and risk profile justify animal confirmation.

Question: Why are both polar and non-polar extraction solvents required?

Answer: Leachables from polymeric consumables span a wide polarity range, from water-soluble ions and residual monomers to lipophilic plasticizers and oligomers. Using both polar and non-polar or mixed solvent systems ensures that hydrophilic and hydrophobic genotoxicants are captured and presented to the biological test systems.

Question: How is cytotoxicity of extracts managed during testing?

Answer: Dose-finding experiments establish the highest concentration that does not cause excessive cytotoxicity or precipitation, and the definitive study tests concentrations spanning this limit. Cytotoxicity parameters such as relative survival, relative population doubling, or replication index are reported alongside genotoxicity endpoints so reviewers can distinguish specific genotoxicity from nonspecific toxicity.

Question: What is a typical turnaround time?

Answer: The Ames test generally requires four to six weeks from extract availability, in vitro chromosomal aberration or micronucleus tests approximately eight to twelve weeks, and in vivo micronucleus studies three to four months including animal work. Integrated programs combining chemical characterization and biological testing should be planned over several months to align with submission timelines.

Question: Can chemical characterization replace biological genotoxicity testing?

Answer: Chemical characterization per ISO 10993-18 with toxicological risk assessment can justify reducing or omitting certain biological tests when all extractable substances are identified and quantified below established safety thresholds, including mutagenic thresholds of toxicological concern. However, for many device categories and regulatory pathways, baseline Ames testing remains expected, and unresolved extractable mixtures typically require the standard biological battery.